NCT03416270View on ClinicalTrials.gov

ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

June 28, 2018

Primary Completion Date

April 14, 2021

Study Completion Date

April 14, 2021

Conditions
Type 2 Diabetes MellitusHeart Failure
Interventions
DRUG

Ertugliflozin

Ertugliflozin Tablets Total Dose 15mg (10mg + 5 mg) once daily for 12 weeks

DRUG

Placebo

Placebo once daily for 12 weeks

Trial Locations (3)

1117

Vanderbilt University Medical Centre, Amsterdam

M5G2N2

Toronto General Hospital, Toronto

Unknown

University Medical Center Groningen, Groningen

All Listed Sponsors
collaborator

University Medical Center Groningen

OTHER

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

University of Toronto

OTHER

collaborator

Toronto General Hospital

OTHER

lead

University Health Network, Toronto

OTHER

NCT03416270 - ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure | Biotech Hunter | Biotech Hunter